CM-4307
- Generic Name
- CM-4307
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 1130115-44-4
- Unique Ingredient Identifier
- 41XGO0VS1U
- Background
CM-4307 is under investigation in clinical trial NCT03602495 (Donafenib in 131I-Refractory Differentiated Thyroid Cancer).
- Indication
用于治疗既往未接受过全身系统性治疗的不可手术切除或转移性肝细胞癌患者。
Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: TACEDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-08
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT05717738
- Locations
- 🇨🇳
Optical Valley branch of Tongji hospital, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Combined HAIC, TKI/anti-VEGF and ICIs As Conversion Therapy for Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Non-resectable
- Interventions
- Procedure: HAICDrug: Anti-PD-1 monoclonal antibody
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ze-yang Ding, MD
- Target Recruit Count
- 300
- Registration Number
- NCT05713994
- Locations
- 🇨🇳
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China
🇨🇳TongjiHospital, Wuhan, Hubei, China
Donafenib Combined With Hepatic Artery Chemoembolization for Perioperative Treatment of Liver Transplantation
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- Beijing Tsinghua Chang Gung Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT05576909
- Locations
- 🇨🇳
Beijing Tsinghua Changgung Hospital, Beijing, China
Study of Donafenib Combined With Tislelizumab in the Adjuvant Treatment of Primary HCC With High Risk of Recurrence
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-09-19
- Last Posted Date
- 2022-09-19
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT05545124
HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Procedure: HAIC(FOLFOX)
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2022-08-18
- Target Recruit Count
- 93
- Registration Number
- NCT05493332
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
- Conditions
- Biliary Tract Adenocarcinoma
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Lu Wang, MD, PhD
- Target Recruit Count
- 70
- Registration Number
- NCT05350943
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
A Real-world Study of Donafenib Combined With TACE-based Treatment in Patients With Unresectable HCC
- Conditions
- Hepatocellular CarcinomaDonafenib
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT05205629
- Locations
- 🇨🇳
Fudan University, Shanghai, China
Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-12-28
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Peking University
- Target Recruit Count
- 156
- Registration Number
- NCT05171166
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2021-12-22
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 30
- Registration Number
- NCT05166772
Donafenib Combined With TACE as Adjuvant Therapy of Patients With Hepatocellular Carcinoma
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2021-12-17
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT05161143
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.